HEREDITARY ANGIOEDEMA
Clinical trials for HEREDITARY ANGIOEDEMA explained in plain language.
Never miss a new study
Get alerted when new HEREDITARY ANGIOEDEMA trials appear
Sign up with your email to follow new studies for HEREDITARY ANGIOEDEMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New HAE drug shows promise in early trial
Disease control CompletedThis study tested a new drug called navenibart (STAR-0215) in 29 adults with hereditary angioedema (HAE), a condition causing painful swelling attacks. Participants received one or two doses to check safety and how well it reduces attacks. The goal is to find a treatment that con…
Matched conditions: HEREDITARY ANGIOEDEMA
Phase: PHASE1, PHASE2 • Sponsor: Astria Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 06:56 UTC
-
New pill could stop debilitating HAE attacks in their tracks
Disease control CompletedThis study tested an oral medication called BCX4161 to prevent sudden swelling attacks in people with hereditary angioedema (HAE), a rare genetic condition. About 110 adults with HAE type I or II took either a low dose, high dose, or placebo daily for 12 weeks. Researchers tracke…
Matched conditions: HEREDITARY ANGIOEDEMA
Phase: PHASE2, PHASE3 • Sponsor: BioCryst Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 06:47 UTC
-
Promising HAE treatment shows safety in extended dosing trial
Disease control CompletedThis study looked at the safety and effectiveness of a drug called donidalorsen for people with hereditary angioedema (HAE), a condition that causes sudden, severe swelling. Twenty participants who completed a previous study received the drug for up to 64 weeks. The main goal was…
Matched conditions: HEREDITARY ANGIOEDEMA
Phase: PHASE2 • Sponsor: Ionis Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 26, 2026 06:46 UTC
-
New pill shows promise for kids with rare swelling disorder
Disease control CompletedThis study tested an oral medicine called sebetralstat in 36 children aged 2 to 11 with hereditary angioedema (HAE) Types I or II, a condition causing sudden, painful swelling attacks. The main goal was to check safety and how the body processes the drug. Researchers also measure…
Matched conditions: HEREDITARY ANGIOEDEMA
Phase: PHASE3 • Sponsor: KalVista Pharmaceuticals, Ltd. • Aim: Disease control
Last updated May 26, 2026 06:44 UTC
-
New shot keeps rare swelling disease in check for months
Disease control CompletedThis study tested a monthly injection called Garadacimab to prevent painful swelling attacks in people with hereditary angioedema (HAE). 171 people aged 12 and older took part. The goal was to see if the drug is safe and effective over the long term. Results showed it can greatly…
Matched conditions: HEREDITARY ANGIOEDEMA
Phase: PHASE3 • Sponsor: CSL Behring • Aim: Disease control
Last updated May 18, 2026 12:01 UTC
-
New pill could stop swelling attacks in their tracks
Symptom relief CompletedThis study tested an oral medication called deucrictibant for treating sudden swelling attacks in people with hereditary angioedema (HAE), a rare genetic condition. The trial involved 134 adolescents and adults aged 12 to 75 who took either the drug or a placebo at the start of a…
Matched conditions: HEREDITARY ANGIOEDEMA
Phase: PHASE3 • Sponsor: Pharvaris Netherlands B.V. • Aim: Symptom relief
Last updated May 26, 2026 06:49 UTC
-
New pill could quickly ease swelling attacks in rare genetic condition
Symptom relief CompletedThis study tested an oral medication called deucrictibant for treating sudden swelling attacks in people with hereditary angioedema (HAE) types I and II. 74 adults received either one of three doses of the drug or a placebo during an attack. The main goal was to see if the drug r…
Matched conditions: HEREDITARY ANGIOEDEMA
Phase: PHASE2 • Sponsor: Pharvaris Netherlands B.V. • Aim: Symptom relief
Last updated May 26, 2026 06:47 UTC
-
Real-World data on HAE attack treatment collected in completed study
Knowledge-focused CompletedThis study followed 88 people with hereditary angioedema (HAE) types I or II who already use icatibant for sudden attacks. Participants filled out diaries for 48 hours after each attack to report symptom changes and anxiety levels. The goal was to understand how well icatibant wo…
Matched conditions: HEREDITARY ANGIOEDEMA
Sponsor: KalVista Pharmaceuticals, Ltd. • Aim: Knowledge-focused
Last updated May 18, 2026 12:13 UTC